Monte Rosa Therapeutics, Inc. (GLUE)
Nasdaq: GLUE · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2020
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 17, 2026 | Mar 20, 2025 | Mar 14, 2024 | Mar 16, 2023 | Mar 29, 2022 | · |
| Revenue | 123,672 | 75,622 | 0 | · | · | · |
| Research and development | 141,500 | 121,563 | 111,272 | 85,061 | 57,155 | 24,005 |
| General and administrative | 36,380 | 35,171 | 32,039 | 27,323 | 15,727 | 4,005 |
| Total operating expenses | 177,880 | 156,734 | 143,311 | 112,384 | 72,882 | 28,010 |
| Operating income | -54,208 | -81,112 | -143,311 | -112,384 | -72,882 | -28,010 |
| Interest income (expense), net | 12,942 | 10,566 | 9,334 | 3,764 | 46 | 9 |
| Total non-operating income (expense) | 14,485 | 10,982 | 8,297 | 3,883 | -1,076 | -7,869 |
| Income before income taxes | -39,723 | -70,130 | -135,014 | -108,501 | · | · |
| Income tax expense | -1,097 | 2,570 | 338 | 0 | · | · |
| Net income including non-controlling interests | -38,626 | -72,700 | -135,352 | -108,501 | -73,958 | -35,879 |
| Net income | -38,626 | -72,700 | -135,352 | -108,501 | -73,958 | -35,879 |
| Earnings per share, basic and diluted | · | · | · | · | -2.96 | -23.65 |
| Weighted average shares, basic | 83,071,185 | 73,910,026 | 51,396,961 | 47,227,370 | 25,000,124 | · |
| Weighted average shares, diluted | 83,071,185 | 73,910,026 | 51,396,961 | 47,227,370 | 25,000,124 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 25,000,124 | 1,516,912 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted